Epilepsy Trial, Recruiting (NCT04526093)

Epilepsy Trial, Recruiting NCT04526093 Sponsor: University Health Network, Toronto Condition: Epilepsy

Printed from Voxsanity (voxsanity.com.au) — NCT04526093 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Epilepsy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 19 or older who have been authorised to use medical cannabis by a healthcare practitioner, whether or not they have used medical cannabis before, and who have given their consent to participate
People whose main reason for using medical cannabis is to help with pain, epilepsy, sleep problems, and/or anxiety or depression
People who agree to use only the specific cannabis products provided by the trial and to avoid all other cannabis products, whether medical or recreational, for the entire duration of the study

Who may not be able to join:

People who are currently using illegal drugs
People who are currently using recreational cannabis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hance Clarke, MD, PhD, Toronto General Hospital, UHN

Phone: 416-340-4800 X 4251

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04526093

Sponsor: University Health Network, Toronto

Phase: Not Applicable

Status: Recruiting

Condition: Epilepsy

Trial contact: 416-340-4800 X 4251

More information: https://clinicaltrials.gov/study/NCT04526093

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 19 or older who have been authorised to use medical cannabis by a healthcare practitioner, whether or not they have used medical cannabis before, and who have given their consent to participate
People whose main reason for using medical cannabis is to help with pain, epilepsy, sleep problems, and/or anxiety or depression
People who agree to use only the specific cannabis products provided by the trial and to avoid all other cannabis products, whether medical or recreational, for the entire duration of the study

Who may not be able to join:

People who are currently using illegal drugs
People who are currently using recreational cannabis

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Health Network, Toronto

Registry

ClinicalTrials.gov

Start date

15 July 2020

Est. completion

1 March 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in pain intensity from baseline to week 24 post-authorization of MC: Measured using the numerical rating scale (NRS).; Change in pain interference from baseline to week 24 post-authorization of MC: Measured using the Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Interference short form 6a.; Sleep: Change in the Pittsburgh Sleep Quality Index (PSQI) from baseline to week 24 post-authorization of MC; Anxiety: Change in the symptoms from baseline to week 24 post-authorization of MC; Measured using Generalized Anxiety Disorder 7-item scale (GAD-7).; Depression: Chan...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov